Over Warming Syndrome in Adults

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
X. Han-You
Keyword(s):  
Quality Of Life ◽  
Clinical Medicine ◽  
Clinical Symptoms ◽  
New Methods ◽  
Treatment And Prevention ◽  
Normal People ◽  
Health Level ◽  
And Behavior ◽  
Harmful Effects

Clinical significance:This article implicates that doctors must know the Over Warming Syndrome in Adults’ harmful effects, its clinical managements, imperative importance to prevent other critical diseases attacks. So that the doctors can do patient and normal people education, counsel about the new syndrome, enhance people's health level and quality of life.Objectives:Name a new kind of syndrome, in order to provide new methods of thinking and behavior for doctors to well diagnose, prevent, and treat the syndrome and other diseases and for doctors to do patient education and counseling.Method:Summarize author of this paper the self-experiences about this syndrome's clinical medicine.Results:The etiology, clinical symptoms, mechanism, diagnosis, treatment and prevention of this new syndrome are easy to understand by the doctors. Which like the symptoms of the dehydration caused by over warming.Conclusions:It is very important to name and understand this new syndrome for enhancing the human-being's health level and quality of life, preventing the human-being from development of other critical diseases. which is much too worth to be spread.

scholarly journals QUALITY OF LIFE IN PATIENTS WITH CHRONIC VENOUS DISEASES AND METHODS OF ITS IMPROVEMENT (review)

2018 ◽  
Vol 5 (2) ◽  
pp. 64-68
Author(s):  
N. Pytetska
Keyword(s):  
Quality Of Life ◽  
Drug Therapy ◽  
Work Capacity ◽  
Modern Medicine ◽  
Comprehensive Analysis ◽  
New Methods ◽  
Treatment And Prevention ◽  
Venous Diseases ◽  
History Of

QUALITY OF LIFE IN PATIENTS WITH CHRONIC VENOUS DISEASES AND METHODS OF ITS IMPROVEMENT (review)N.I. Pytetska Assessment of the quality of life is one of the leading directions in modern medicine and continues to develop intensively, remaining an integral part of comprehensive analysis of new methods of diagnosis, treatment and prevention. This article provides information about the history of the concept "quality of life" and the ambiguity of terminology. Particular attention is paid to the necessity of studying this indicator in patients with chronic veins diseases, the relevance of this direction in the early stages of the disease, as well as medicines able to solve the main tasks of drug therapy, to restore work capacity and, as a result improve the patient's life quality.Key words: quality of life, chronic venous diseases, diosmin. ЯКІСТЬ ЖИТТЯ ХВОРИХ НА ХРОНІЧНІ ЗАХВОРЮВАННЯ ВЕН ТА МЕТОДИ ЇЇ ПОКРАЩЕННЯ (огляд)Питецька Н.І.Вивчення якості життя є одним із провідних напрямків сучасної медицини й продовжує інтенсивно розвиватись, залишаючись невід'ємною частиною всебічного аналізу нових методів діагностики, лікування і профілактики. У даній статті представлено інформацію про історію виникнення поняття «якість життя», неоднозначність термінології. Особливуувагу приділено необхідності оцінки даного показника у хворих на хронічні захворювання вен, актуальності цього напрямку на ранніх стадіях захворювання, а також  лікарським засобам, які здатні вирішувати основні завдання медикаментозної терапії, відновлювати працездатність і підвищувати якість життя пацієнта.Ключові слова: якість життя, хронічні захворювання вен, діосмін. КАЧЕСТВО ЖИЗНИ БОЛЬНЫХ С ХРОНИЧЕСКИМИ ЗАБОЛЕВАНИЯМИ ВЕН И МЕТОДЫ ЕГО УЛУЧШЕНИЯ (обзор)Питецкая Н.И.Изучение качества жизни является одним из ведущих направлений современной медицины и продолжает интенсивно развиваться, оставаясь неотъемлемой частью всестороннего анализа новых методов диагностики, лечения и профилактики. В данной статье представлена информация об истории возникновения понятия «качество жизни», неоднозначности терминологии. Особое внимание уделено необходимости оценки данного показателя у больных хроническими заболеванияи вен, актуальности этого направления на ранних стадиях заболевания, а также  лекарственным препаратам, которые способны решать основные задачи медикаментозной терапии, восстанавливать трудоспособность и повышать качество жизни пациента.Ключевые слова: качество жизни, хронические заболевания вен, диосмин. 

CURRENT ASPECTS OF DRUG THERAPY OF CHRONIC HEART FAILURE SYNDROME

2020 ◽  
Vol 4 (2) ◽  
pp. 1085-1096
Author(s):  
T.V. Statkevich ◽  
◽  
N.P. Mitkovskaya ◽  
◽  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Drug Therapy ◽  
Chronic Heart Failure ◽  
Clinical Symptoms ◽  
Nyha Class ◽  
Treatment And Prevention ◽  
One Year ◽  
The One

Chronic heart failure (CHF) is an important problem for the country, which has both medical and socio-economic aspects. The presence of the syndrome not only significantly increases the risks of an unfavorable course of diseases underlying its etiological basis, but in itself, through the development of decompensation, causes a high frequency of deaths. Despite all the advances in pharmacotherapy, the prognosis of heart failure remains poor. More than 40% of patients die within 4 years after the diagnosis of heart failure, and the one-year mortality rate for patients with severe CHF (NYHA class IV) exceeds 50%. The foregoing determines the need and importance of using all possible drug and non-drug therapy technologies aimed at reducing mortality, increasing the duration and quality of life of patients with CHF, as well as reducing the number and likelihood of decompensation and related hospitalizations, and makes this direction one of the priorities in medicine. The article describes current approaches to the treatment of patients with CHF syndrome from the perspective of evidence-based medicine and taking into account the recommendations of leading international organizations for the treatment and prevention of cardiovascular diseases. The drugs used were analyzed in terms of their influence on clinical symptoms, quality of life of patients, the risk of hospitalization due to decompensation of CHF, and mortality rates. The emphasis is made on the possibilities, mechanism of action and further prospects for the use of a new class of drugs in the treatment of CHF, acting at the level of the renin-angiotensin-aldosterone system and the system of neutral endopeptidases - inhibitors of angiotensin-neprilisin receptors.

scholarly journals The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: results from a phase IV study

2021 ◽  
Author(s):  
Tommaso Cai ◽  
Luca Gallelli ◽  
Erika Cione ◽  
Gianpaolo Perletti ◽  
Francesco Ciarleglio ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Symptoms ◽  
Clinical Status ◽  
Well Being ◽  
Antibiotic Use ◽  
Chronic Bacterial Prostatitis ◽  
Symptomatic Recurrence ◽  
Bacterial Prostatitis ◽  
Phase Iv

Abstract Purpose To evaluate the efficacy of Lactobacillus paracasei CNCM I-1572 (L. casei DG®) in both prevention of symptomatic recurrences and improvement of quality of life in patients with chronic bacterial prostatitis (CBP). Methods Patients with CBP attending a single Urological Institution were enrolled in this phase IV study. At enrollment, all patients were treated with antibiotics in agreement with EAU guidelines and then were treated with L. casei DG® (2 capsules/day for 3 months). Clinical and microbiological analyses were carried out before (enrollment, T0) and 6 months (T2) after the treatment. Both safety and adherence to the treatment were evaluated 3 months (T1) after the enrollment. NIH Chronic Prostatitis Symptom Index (CPSI), International Prostate Symptom Score (IPSS) and Quality of Well-Being (QoL) questionnaires were used. The outcome measures were the rate of symptomatic recurrence, changes in questionnaire symptom scores and the reduction of antibiotic use. Results Eighty-four patients were included. At T2, 61 patients (72.6%) reported a clinical improvement of symptoms with a return to their clinical status before symptoms. A time dependent improvement in clinical symptoms with significant changes in NIH-CPSI, IPSS and QoL (mean difference T2 vs T0: 16.5 ± 3.58; − 11.0 ± 4.32; + 0.3 ± 0.09; p < 0.001), was reported. We recorded that L. casei DG® treatment induced a statistically significant decrease in both (p < 0.001) symptomatic recurrence [1.9/3 months vs 0.5/3 months] and antibiotic use [− 7938 UDD]. No clinically relevant adverse effects were reported. Conclusions L. casei DG® prevents symptomatic recurrences and improves the quality of life in patients with CBP, reducing the antibiotic use.

Quality of Life in Patients With Behçet Disease and Its Relation With Clinical Symptoms and Disease Activity

2021 ◽  
Vol 17 (1) ◽  
pp. 1-6
Author(s):  
Alireza Khabbazi ◽  
Vahideh Ebrahimzadeh Attari ◽  
Mohammad Asghari Jafarabadi ◽  
Aida Malek Mahdavi
Keyword(s):  
Quality Of Life ◽  
Disease Activity ◽  
Clinical Symptoms ◽  
Behçet Disease ◽  
Behcet Disease

scholarly journals The quality of life in the relatives of Wolfram’s syndrome patients

2014 ◽  
Vol 5 (1) ◽  
pp. 89-97
Author(s):  
Gema Esteban ◽  
Mónica Ruano ◽  
Isabel Motero
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Genetic Basis ◽  
Clinical Symptoms ◽  
Daily Life ◽  
Wolfram Syndrome ◽  
Clinical Aspects ◽  
The Family ◽  
Low Prevalence

Wolfram Syndrome (WS) is a rare disease (RD) with an estimated prevalence of 1/770,000 inhabitants. It is considered a multisystemic, chronic and progressive disease.WS diagnosis implies devastating consequences at physical, educational and emotional levels. WS is also known by the acronym DIDMOAD, derived from the first letters of the main clinical symptoms: Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness. Rare diseases are characterized by their low prevalence and the lack of knowledge on the pathophysiology and treatment of them. Interestingly, around 80% of RD have a genetic basis, and this fact causes doubts and uncertainties in the couples, about the idea of having another child. The existence of a RD in a family, alters significantly the relationships and the quality of life within the family. The present work remarks the huge value of psychosocial aspects in order to pay an adequate attention to these patients, not only taking care of the clinical aspects. The main purpose of this study has been to ascertain the quality of life of Wolfram’s syndrome affected patients, and its impact in the daily life.

Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care

2008 ◽  
Vol 23 (8) ◽  
pp. 561-566 ◽  
Author(s):  
Ronette L. Kolotkin ◽  
Patricia K. Corey-Lisle ◽  
Ross D. Crosby ◽  
Hong J. Kan ◽  
Robert D. McQuade
Keyword(s):  
Quality Of Life ◽  
Clinical Symptoms ◽  
Clinical Trial Data ◽  
Standard Of Care ◽  
Random Regression ◽  
Sexual Life ◽  
Baseline Body Mass Index ◽  
Meaningful Change ◽  
Related Quality

AbstractBackgroundThis is a secondary analysis of clinical trial data collected in 12 European countries. We examined changes in weight and weight-related quality of life among community patients with schizophrenia treated with aripiprazole (ARI) versus standard of care (SOC), consisting of other marketed atypical antipsychotics (olanzapine, quetiapine, and risperidone).MethodFive-hundred and fifty-five patients whose clinical symptoms were not optimally controlled and/or experienced tolerability problems with current medication were randomized to ARI (10–30 mg/day) or SOC. Weight and weight-related quality of life (using the IWQOL-Lite) were assessed at baseline, and weeks 8, 18 and 26. Random regression analysis across all time points using all available data was used to compare groups on changes in weight and IWQOL-Lite. Meaningful change from baseline was also assessed.ResultsParticipants were 59.7% male, with a mean age of 38.5 years (SD 10.9) and mean baseline body mass index of 27.2 (SD 5.1). ARI participants lost an average of 1.7% of baseline weight in comparison to a gain of 2.1% by SOC participants (p < 0.0001) at 26 weeks. ARI participants experienced significantly greater increases in physical function, self-esteem, sexual life, and IWQOL-Lite total score. At 26 weeks, 20.7% of ARI participants experienced meaningful improvements in IWQOL-Lite score, versus 13.5% of SOC participants. A clinically meaningful change in weight was also associated with a meaningful change in quality of life (p < 0.001). A potential limitation of this study was its funding by a pharmaceutical company.ConclusionsCompared to standard of care, patients with schizophrenia treated with aripiprazole experienced decreased weight and improved weight-related quality of life over 26 weeks. These changes were both statistically and clinically significant.

Sign in / Sign up

Export Citation Format

Share Document